Misonix Incorporated

339 articles with Misonix Incorporated

• Misonix to Present at the 39th Annual J.P. Morgan Healthcare Conference

  12/23/2020

  Misonix, Inc. (Nasdaq: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today announced that it will be participating in the 39 th Annual J.P. Morgan Healthcare Conference. Misonix Chief Executive Officer, Stavros Vizirgianakis, along with Joe Dwyer, Misonix Chief Financial Officer, will be making a virtual company presentation on Thursday, January 14

• Misonix Announces the Second Largest U.S. Commercial Payer Has Provided Coverage for TheraSkin® to Treat All Lower Extremity Dermal Wounds Adding 32 Million New Covered Lives

  12/18/2020

  Misonix, Inc. (NASDAQ: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today announced that the second largest U.S. Commercial payer will now cover Thera S kin for all lower extremity dermal wounds. TheraSkin is a proven cellular and tissue-based treatment for difficult to heal chronic wounds. “This favorable decision by the second larges

• Misonix to Participate at Upcoming Craig-Hallum and Canaccord Genuity Investor Conferences

  11/12/2020

  Misonix, Inc. (NASDAQ: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today announced that it will be participating in the upcoming Craig-Hallum and Canaccord Genuity investor conferences in November. Misonix Chief Executive Officer, Stavros Vizirgianakis, along with Joe Dwyer, Chief Financial Officer, will be available to host one-on-one meetings with

• Misonix Fiscal 2021 First Quarter Revenue Rises 59% to $17.7 Million

  11/5/2020

  Misonix, Inc., a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, reported unaudited financial results for the fiscal 2021 first quarter ended September 30, 2020 as summarized below:

• Misonix to Report Fiscal 2021 First Quarter Financial Results and Host Conference Call and Webcast on November 5

  10/20/2020

  Misonix, Inc.  (NASDAQ: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, announced today that it will report its fiscal 2021 first quarter financial results after the market closes on Thursday, November 5, 2020. The Company will host a conference call and webcast at 4:30 p.m. ET that day to review the results. Both the call and webcast are open to the ge

• Misonix Reports Preliminary Fiscal 2021 First Quarter Revenue of Approximately $17.7 MillionConfirms Improving Revenue Trends, Rise in Procedure Volumes and Strong New Product Adoption

  10/6/2020

  Misonix, Inc., a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, announced preliminary unaudited revenue for the first quarter of its fiscal year 2021 ended September 30, 2020.

• Misonix Enters Into Exclusive Supply and Distribution Agreement With Gunze Limited for TheraGenesis® Bilayer Wound MatrixExpands Misonix’s Wound Tissue Regeneration Franchise and Complements Nexus SonicOne® Strategy

  9/21/2020

  Misonix, Inc. (Nasdaq: MSON) (“Misonix”) a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative tissue products that enhance clinical outcomes, announced today that it has entered into an exclusive supply and distribution agreement with Gunze Limited for TheraGenesis ® Bilayer Wound Matrix. TheraGenesis is a proprietary, FDA cleared, porcine tendon derived collagen wound matrix with a silicone film layer

• Misonix to Present at the Cantor Virtual Global Healthcare Conference

  9/9/2020

  Misonix, Inc. (Nasdaq: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today announced that it will be participating in the Cantor Virtual Global Healthcare  Conference.

• Misonix Reports Fourth Quarter and Fiscal Year 2020 Results

  9/3/2020

  Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today reported unaudited financial results for the fiscal 2020 fourth quarter and full fiscal year ended June 30, 2020 as summarized below:   Three Months Ended   Year Ended   June 30,   June 30,     2020     2019       2020

• Misonix to Report Fiscal 2020 Fourth Quarter Financial Results and Host Conference Call and Webcast on September 3

  8/6/2020

  Misonix, Inc. (NASDAQ: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, announced today that it will report its fiscal 2020 fourth quarter financial results after the market closes on Thursday, September 3, 2020. The Company will host a conference call and webcast at 4:30 p.m. ET that day to review the results. Both the call and webcast are open to th

• Misonix to Present at the 40th Annual Canaccord Genuity Growth Conference

  7/30/2020

  Misonix, Inc. (Nasdaq: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today announced that it will be participating in the 40 th Annual Canaccord Genuity Growth Conference. Misonix Chief Executive Officer, Stavros Vizirgianakis, along with Joe Dwyer, Misonix Chief Financial Officer, will be making a virtual company presentation on Wednesday, August

• Misonix Reports Preliminary Fiscal 2020 Fourth Quarter Revenue of Approximately $13.5 Million

  7/10/2020

  Company Focus on Shareholder Value Creation, Cash Preservation, Expense Reduction, Workforce Efficiency and Operational Synergies

• Misonix to Present at the 17th Annual Craig Hallum Institutional Investor Conference On May 27

  5/22/2020

  Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today announced that it will be participating in the 17th Annual Craig Hallum Institutional Investor Conference taking place on Wednesday, May 27, 2020. Misonix President and Chief Executive Officer, Stavros Vizirgianakis, along with Joe Dwyer, Misonix

• Misonix Fiscal 2020 Third Quarter Revenue Rises to $17.9 Million

  5/11/2020

  Misonix, Inc., a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, reported financial results for the fiscal 2020 third quarter ended March 31, 2020 as summarized below:

• Misonix to Report Fiscal 2020 Third Quarter Financial Results and Host Conference Call and Webcast on May 11

  5/6/2020

  Misonix, Inc., a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, announced that it will report its fiscal 2020 third quarter financial results after the market closes on Monday, May 11, 2020.

• Misonix to Present at the 40th Annual Cowen Healthcare Conference on March 2

  2/18/2020

  FARMINGDALE, N.Y., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that enhance clinical outcomes, today announced that it will be participating in the 40 th Annual Cowen Healthcare Conference taking place on Monday, March 2 nd at the Boston Marriott Copley Place hotel in Boston. Misonix President and Chief Executive Officer, Stavros Vizirgianakis, along with Joe Dwyer, Mi

• Misonix Announces Public Offering of Common Stock - Jan. 22, 2020

  1/22/2020

  Misonix, Inc., a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, announced that it has commenced an underwritten public offering of its common stock.

• Misonix Reports Preliminary Fiscal 2020 Second Quarter Revenue of Approximately $19.7 MillionReiterates Expectation for Fiscal 2020 Full Year Pro Forma Revenue Growth of 20%

  1/13/2020

  Misonix, Inc. announced preliminary unaudited fiscal 2020 second quarter revenue for the three months ended December 31, 2019 of approximately $19.7 million.

• CryoLife and Misonix Enter Into Distribution Agreement for NeoPatch

  12/19/2019

  CryoLife, Inc. announced that it has entered into an agreement whereby Misonix will have exclusive US commercialization rights for CryoLife's NeoPatch product to treat a broad range of indications outside of cardiac and vascular surgery.

• Misonix to Present at 38th Annual J.P. Morgan Healthcare Conference

  12/17/2019

  38th Annual J.P. Morgan Healthcare Conference being held January 13-16, 2020, at the Westin St. Francis Hotel in San Francisco, California.